Market Place
Sourcing Support
NeuroSense Gets FDA Support For PrimeC Phase 3 Trial Design
11 Dec 2024 //
PR NEWSWIRE
NeuroSense PARADIGM Study Highlights PrimeC Benefits In ALS
04 Dec 2024 //
PR NEWSWIRE
NeuroSense Therapeutics to Present at ALS/MND Symposium 2024
21 Nov 2024 //
PR NEWSWIRE
NeuroSense Advances Phase 3 ALS Trial and NDA Submission
28 Oct 2024 //
PR NEWSWIRE
New Analysis Shows PrimeC Improves miRNAs In ALS Patients
24 Oct 2024 //
PR NEWSWIRE
NeuroSense Advances Plans For ALS Treatment Commercialization
15 Oct 2024 //
PR NEWSWIRE
NeuroSense Plans To File For Early Commercialization In Canada
09 Oct 2024 //
PR NEWSWIRE
NeuroSense Announces Acceptance Of Two PrimeC Abstracts At NEALS 2024
07 Oct 2024 //
PR NEWSWIRE
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
24 Sep 2024 //
PR NEWSWIRE
NeuroSense Granted Key U.S. Patent for PrimeC in ALS, Alzheimer`s
24 Sep 2024 //
PR NEWSWIRE
NeuroSense Therapeutics Receives Nasdaq Minimum Bid Price Notification
30 Aug 2024 //
PR NEWSWIRE
NeuroSense Therapeutics Announces Private Placement At Premium
07 Aug 2024 //
PR NEWSWIRE
NeuroSense Reports Positive ALS Phase 2b Biomarker Data
01 Aug 2024 //
PR NEWSWIRE
NeuroSense`s ALS Trial Shows Improved Survival And Slowed Progression
09 Jul 2024 //
PR NEWSWIRE
NeuroSense Reports Positive 12-Month PARADIGM Study Results For PrimeC
01 Jul 2024 //
PR NEWSWIRE
NeuroSense Management Provides Corporate Update And Q1 2024 Financial Results
24 Jun 2024 //
PR NEWSWIRE
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal
21 Jun 2024 //
PR NEWSWIRE
NeuroSense`s Zimri At ALS Drug Development Summit
20 May 2024 //
PR NEWSWIRE
NeuroSense Partners With PhaseV For Optimized ALS Phase 3 Trial
14 May 2024 //
PR NEWSWIRE
NeuroSense Positive ALS Progression Data From PARADIGM
07 May 2024 //
PR NEWSWIRE
NeuroSense Announces First Quarter 2024 Business Update
02 May 2024 //
PR NEWSWIRE
NeuroSense, Genetika+ Precision Medicine Alzheimer`s Collaboration
22 Apr 2024 //
PR NEWSWIRE
NeuroSense Presenting PARADIGM Data At AAN 2024
12 Apr 2024 //
PR NEWSWIRE
NeuroSense Pricing $4.5M Offering and Private Placement
10 Apr 2024 //
PR NEWSWIRE
NeuroSense, Lonza Partner On Exosome Biomarkers, Neurodegeneration
09 Apr 2024 //
PR NEWSWIRE
Lonza, NeuroSense Enter Alliance for ALS Candidate
09 Apr 2024 //
CONTRACTPHARMA
NeuroSense Announces Year End 2023 Financial Results
05 Apr 2024 //
PR NEWSWIRE
NeuroSense Reports Positive Results from its ALS Phase 2b PARADIGM Trial
21 Feb 2024 //
PR NEWSWIRE
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
07 Feb 2024 //
PR NEWSWIRE
NeuroSense`s Phase 2b ALS Trial Achieves Clinical Efficacy Endpoints
05 Dec 2023 //
PR NEWSWIRE
NeuroSense to Report Phase 2b ALS Topline Primary Safety Endpoints
04 Dec 2023 //
PR NEWSWIRE
NeuroSense Announces Third Quarter 2023 Financial Results
28 Nov 2023 //
PR NEWSWIRE
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC
13 Nov 2023 //
PR NEWSWIRE
NeuroSense Completes Dosing of Last Patient in Phase 2b ALS Trial
06 Nov 2023 //
PR NEWSWIRE
NeuroSense Therapeutics to Participate in BIO-Europe Fall
01 Nov 2023 //
PR NEWSWIRE
NeuroSense`s PrimeC Demonstrates Outstanding Effect on ALS Survival
04 Oct 2023 //
PR NEWSWIRE
NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC
19 Sep 2023 //
PR NEWSWIRE
NeuroSense to Participate in Upcoming ALS Conferences
14 Sep 2023 //
PR NEWSWIRE
NeuroSense Announces Second Quarter 2023 Financial Results
16 Aug 2023 //
PR NEWSWIRE
NeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023
17 Jul 2023 //
PR NEWSWIRE
NeuroSense to Participate in Upcoming ALS Conferences
11 Jul 2023 //
PR NEWSWIRE
NeuroSense CEO Provides Q2 2023 Update
06 Jul 2023 //
PR NEWSWIRE
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering
22 Jun 2023 //
PR NEWSWIRE
On lookout for ALS biomarker, Biogen pens Israeli biotech pact
15 Jun 2023 //
FIERCE BIOTECH
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
15 May 2023 //
PR NEWSWIRE
NeuroSense makes key progress in Phase II ALS trial
15 May 2023 //
CLINICAL TRIALS ARENA
NeuroSense reports encouraging preliminary results from PD study
02 May 2023 //
CLINICAL TRIALS ARENA
NeuroSense Reports Positive Preliminary Results in Parkinson`s Biomarker Study
02 May 2023 //
PR NEWSWIRE
NeuroSense & Massachusetts General Hospital`s NeuroEpigenetics to Collaborate
27 Mar 2023 //
PR NEWSWIRE
NeuroSense to Present at the ALS and Alzheimer`s Disease at AD/PD 2023 Advances
23 Mar 2023 //
PR NEWSWIRE
NeuroSense Announces Year End 2022 Financial Results & Provides Business Update
22 Mar 2023 //
PR NEWSWIRE
NeuroSense Therapeutics to Participate in BIO-Europe Spring
16 Mar 2023 //
PR NEWSWIRE
NeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts
13 Feb 2023 //
PR NEWSWIRE
NeuroSense and QuantalX Collaborate for Treatment of Neurodegenerative Diseases
09 Feb 2023 //
PR NEWSWIRE
NeuroSense Receives Approval in Germany to Enroll Patients in Phase 2b ALS Trial
08 Feb 2023 //
PR NEWSWIRE
NeuroSense Reports Positive Final Results from Alzheimer`s Biomarker Study
19 Jan 2023 //
PR NEWSWIRE
NeuroSense Announces Third Quarter 2022 Financial Results
01 Dec 2022 //
PRNEWSWIRE
NeuroSense Receives Regulatory Approval for its Phase 2b Trial in ALS
16 Nov 2022 //
PRNEWSWIRE
NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study
15 Nov 2022 //
PRNEWSWIRE
NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences
27 Oct 2022 //
PRNEWSWIRE
